Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (161-170 of 386) with videos related to

Pageof 39
Sort By:
Leukemia Research|February 2, 2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisTri K Nguyen, Nicholas Jordan, Jonathan Friedberg, et al.
Molecular Cancer Therapeutics|September 21, 2014
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsGirija Dasmahapatra, Hiral Patel, Johnathan Friedberg, et al.
Leukemia Research|December 4, 2014
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cellsTri Nguyen, Elisa Hawkins, Akhil Kolluri, et al.
Cancer Research|December 18, 2003
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cellsMohamed Rahmani, Chunrong Yu, Yun Dai, et al.
Molecular Cancer Therapeutics|June 5, 2019
Retraction: <i>In Vitro</i> and <i>In Vivo</i> Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma CellsGirija Dasmahapatra, Hiral Patel, Johnathan Friedberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2014
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivoMohamed Rahmani, Mandy Mayo Aust, Elisa C Benson, et al.
Organic & Biomolecular Chemistry|June 21, 2013
Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myelomaKai Liu, Datong Zhang, Jeremy Chojnacki, et al.
Oncogene|September 19, 2003
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibitionMohamed Rahmani, Chunrong Yu, Erin Reese, et al.
Cancer Research|January 10, 2002
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cellsChunrong Yu, Geoffrey Krystal, Lyuba Varticovksi, et al.
Molecular Pharmacology|January 6, 2012
Obatoclax and lapatinib interact to induce toxic autophagy through NOXAYong Tang, Hossein A Hamed, Nichola Cruickshanks, et al.
Pageof 39

Showing results (161-170 of 386) with videos related to

Sort By:
Pageof 39
Leukemia Research|February 2, 2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisTri K Nguyen, Nicholas Jordan, Jonathan Friedberg, et al.
Molecular Cancer Therapeutics|September 21, 2014
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsGirija Dasmahapatra, Hiral Patel, Johnathan Friedberg, et al.
Leukemia Research|December 4, 2014
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cellsTri Nguyen, Elisa Hawkins, Akhil Kolluri, et al.
Cancer Research|December 18, 2003
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cellsMohamed Rahmani, Chunrong Yu, Yun Dai, et al.
Molecular Cancer Therapeutics|June 5, 2019
Retraction: <i>In Vitro</i> and <i>In Vivo</i> Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma CellsGirija Dasmahapatra, Hiral Patel, Johnathan Friedberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2014
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivoMohamed Rahmani, Mandy Mayo Aust, Elisa C Benson, et al.
Organic & Biomolecular Chemistry|June 21, 2013
Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myelomaKai Liu, Datong Zhang, Jeremy Chojnacki, et al.
Oncogene|September 19, 2003
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibitionMohamed Rahmani, Chunrong Yu, Erin Reese, et al.
Cancer Research|January 10, 2002
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cellsChunrong Yu, Geoffrey Krystal, Lyuba Varticovksi, et al.
Molecular Pharmacology|January 6, 2012
Obatoclax and lapatinib interact to induce toxic autophagy through NOXAYong Tang, Hossein A Hamed, Nichola Cruickshanks, et al.
Pageof 39